Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 11/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24673138 | 1.00 | AHCY (0.59) | AHCYADORA2AADORA3PI4K2ASLC28A1 | |
| SCHEMBL25566624 | 0.75 | SLC28A1 (0.60) | AHCYADORA2AADORA3PI4K2ASLC28A1 | |
| SCHEMBL19503944 | 0.75 | SLC28A1 (0.60) | AHCYADORA2AADORA3PI4K2ASLC28A1 | |
| SCHEMBL12149495 | 0.75 | AHCY (0.86) | AHCYADORA2AADORA3SLC28A1SLC28A2 | |
| SCHEMBL29430167 | 0.75 | AHCY (1.00) | AHCYADORA2AADORA3ADORA2B | |
| SCHEMBL12280207 | 0.75 | AHCY (1.00) | AHCYADORA2AADORA3ADORA2B | |
| SCHEMBL10459031 | 0.75 | AHCY (1.00) | AHCYADORA2AADORA3ADORA2B | |
| SCHEMBL12280226 | 0.75 | AHCY (1.00) | AHCYADORA2AADORA3ADORA2B | |
| SCHEMBL10432751 | 0.75 | AHCY (1.00) | AHCYADORA2AADORA3ADORA2B | |
| SCHEMBL2421602 | 0.75 | AHCY (1.00) | AHCYADORA2AADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220275018-A1 | NOVEL SPIROBICYCLIC INTERMEDIATES | NME2, SLC28A1, SLC28A2 | AHCY 998/4885ADORA2A 148/4885ADORA3 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.